|
|
|
|
|
|
Andrew joined Health Advances in 2005 with a strong background in corporate strategy and
strategic planning. Prior to Health Advances, Andrew worked with Michael Porter of the
Harvard Business School on business strategy and healthcare policy, and with Monitor Group,
where he split his time between the Pharmaceutical and Corporate Finance practices. He
also worked in Genentech’s internal strategic planning group.
At Health Advances, Andrew has led several dozen projects for pharmaceutical and biotech
companies, medical device manufacturers, and private equity investors. He has particular
expertise in helping companies formulate clinical development and commercialization
strategies to maximize the value of new therapeutics. In his nonprofit work, Andrew has
assisted both the National Parkinson Foundation and the Michael J. Fox Foundation with
major strategic planning projects.
Andrew earned an AB in economics, summa cum laude, and a minor in operations research
from Princeton University, and an MBA with distinction from the Harvard Business School.
|
|
 |
|
|
|
|
